TREAMENT OF EARLY AGE MANIA (TEAM)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的总体目标是对患有DSM-IV(躁狂症或混合期)或躁狂症的6.0-15岁(N=540)的人进行一项协作性的、多地点的精神药理学有效性研究。该方案的具体目标是：(1)研究锂、丙戊酸盐和利培酮作为单一治疗和作为附加药物治疗儿童BP-1(躁狂期或混合期)障碍的有效性(2)试验复杂的、多层次的适应性策略设计(3)探讨心理社会因素对停药、依从性和结局的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall aim of this study is to perform a collaborative, multisite psychopharmacology effectiveness study of 6.0-15 years old (N=540) who have DSM-IV (mania or mixed phase) or mania. The specific aims of this protocol are: (1) To investigate the effectivness of lithium, valproate and resperidone as monotherapy and as add-on agents for childhood BP-1 (manic or mixed phase) disorder (2) To pilot a complex, multistrata, adaptive strategy design (3) to explore the effects of psychosocial factors on discontinuation, compliance and outcome.